Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | BCR | P11274 | 3/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7843556 | 0.84 | MGLL (0.47) | MAPTRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL4861321 | 0.81 | MALT1 (0.34) | MALT1BLMMAPTRAB9ANPC1 | |
| SCHEMBL22831640 | 0.79 | MEN1 (0.44) | MAPTCYP2C9PKMRAB9ANPC1 | |
| SCHEMBL20162925 | 0.78 | SCD (0.44) | P2RX7 | |
| SCHEMBL30036352 | 0.78 | SCD (0.44) | P2RX7 | |
| SCHEMBL4861330 | 0.72 | NPY2R (0.35) | BLMMAPTCYP2C9PKMCYP2C19 | |
| SCHEMBL7843554 | 0.72 | P2RX7 (0.37) | MALT1MAPTCYP2C9CYP2C19RAB9A | |
| SCHEMBL20162982 | 0.72 | NOTUM (0.54) | KMT2AMEN1P2RX7 | |
| SCHEMBL30038209 | 0.72 | NOTUM (0.54) | KMT2AMEN1P2RX7 | |
| SCHEMBL3753454 | 0.70 | MGLL (0.49) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2008143649-A2 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | OXA1L, MIF, VIP | MALT1 1352/4885BLM 4043/4885MAPT 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.